Fartoux Laetitia, Rosmorduc Olivier
Service d'Hépato-Gastro-Entérologie, Hôpital de la Pitié-Salpêtrière, 83 boulevard de l'Hôpital, 75013, Paris, France.
Biol Aujourdhui. 2018;212(3-4):85-87. doi: 10.1051/jbio/2018027. Epub 2019 Apr 11.
The treatment of advanced hepatocellular carcinoma has long been hopeless due to an absence of effective molecules and an underlying cirrhosis, compromising tolerance to conventional chemotherapy. A targeted anti-angiogenic therapy, sorafenib, has been the only option for a decade before new oral molecules have been finally validated. Immunotherapy, intended to correct the immunosuppressive context frequently associated with this tumor, has shown very promising results and could profoundly challenge the therapeutic algorithm of advanced hepatocellular carcinoma.
由于缺乏有效的分子以及潜在的肝硬化，晚期肝细胞癌的治疗长期以来一直没有希望，这也影响了对传统化疗的耐受性。在新的口服分子最终得到验证之前的十年里，靶向抗血管生成疗法索拉非尼一直是唯一的选择。旨在纠正常与这种肿瘤相关的免疫抑制环境的免疫疗法已显示出非常有前景的结果，并且可能会深刻挑战晚期肝细胞癌的治疗方案。
